Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

United Technologies Updates FY12 Outlook - Quick Facts

United Technologies Corp. (UTX: Quote) updated its financing plan for the proposed $16.5 billion cash acquisition of Goodrich Corp. (GR: Quote), including expected proceeds of approximately $3 billion from net divestitures and $1.5 billion from mandatory convertible instruments.

UTC businesses identified for sale include Pratt & Whitney Rocketdyne, Clipper Windpower and the Hamilton Sundstrand Industrial businesses: Milton Roy, Sullair and Sundyne. These businesses are treated as held for sale and have been moved to discontinued operations in UTC's financial statements. Gains realized at the time of closing are expected to be greater than impairment charges in discontinued operations, United Technologies said.

Including Goodrich, the company now expects earnings from continuing operations in 2012 of $5.30 to $5.50 per share, up 0 to 4 percent. On the same basis, the company now expects 2012 sales of $61 billion to $62 billion, up 9 to 11 percent and cash flow from operations less capital expenditures to equal or exceed net income attributable to common shareowners.

Analysts polled by Thomson Reuters expect the company to report earnings of $5.59 per share on revenues of $65.56 billion for fiscal 2012. Analysts' estimates typically exclude special items.

While announcing the fourth-quarter results, the company maintained its 2012 forecast for earnings in a range of $5.80 to $6.00 per share, up 6 to 9 percent from last year, for its base business excluding the pending Goodrich transaction. The company maintained full-year sales forecast between $59 billion and $60 billion.

United Technologies agreed in September last year to acquire aerospace components and systems supplier Goodrich for $127.50 per share in an all-cash deal valued at $18.4 billion, including net assumed debt of $1.9 billion. The acquisition is expected to close in mid-2012.

Register
To receive FREE breaking news email alerts for United Technologies Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.